Drug Trial Radar · NCT07873463
Flutemetamol F 18 Injection Formulation Comparison
Last checked: Nov 19, 2026Latest source record: Nov 5, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
20
Planned (sponsor's estimate)
Start
Sep 30, 2026
Primary completion
Feb 25, 2027
Study completion Feb 25, 2027
Sponsor
- Lead sponsor
- GE HealthcareIndustry
- Sponsor type
- Industry
- Collaborators
- PSI CRO
- First posted
- Oct 14, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Crossover
- Masking
- Single (outcomes assessor)
- Primary purpose
- Diagnostic
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 50 years, up to 110 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
VIZAMYL (flutemetamol F 18 injection) is a drug used during Positron Emission Tomography (PET) brain scans. It helps doctors detect the presence of amyloid protein, which is associated with Alzheimer's disease and other conditions affecting memory or thinking. A new formulation of this drug, called GE-287, has been developed. This new formulation may offer advantages for patient tolerability and can be produced more reliably and efficiently. The aim of the study is to determine whether the new formulation works as well as the current one in identifying amyloid in the brain, how it distributes in the body, and whether it is safe for use. The study will measure how much of the study drug goes to different organs (including the brain, heart, liver, and kidneys) and monitor for any side effects.
Conditions
- Cognitive Dysfunction
Interventions
GE-287Drug
Drug: GE-287 185 MBq (±10%) of GE-287 administered intravenously
VizamylDrug
Drug: Vizamyl 185 MBq (±10%) of Vizamyl administered intravenously
VizamylDrug
Drug: Vizamyl 185 MBq (±10%) of Vizamyl administered intravenously
GE-287Drug
Drug: GE-287 185 MBq (±10%) of GE-287 administered intravenously
Primary outcomes
What the sponsor says the trial is designed to measure.
- Comparison of Standard Uptake Value ratio in frontal and anterior cingulate brain regionTime frame: 90-100 minutes after product administration
- Comparison of SUVr in posterior cingulate and precuneus brain regionTime frame: 90-100 minutes after product administration
- Comparison of SUVr in lateral temporal brain regionTime frame: 90-100 minutes after product administration
- Comparison of SUVr in inferolateral parietal brain regionTime frame: 90-100 minutes after product administration
- Comparison of Standard Uptake Value (SUV) in heartTime frame: 0-60 minutes after product administration
- Comparison of SUV in liverTime frame: 0-60 minutes after product administration
- Comparison of SUV in kidneysTime frame: 0-60 minutes after product administration
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Visionary Investigator Network
Aventura, Florida · Recruiting
Meritt Island Research, LLC dba. Flourish Research
Merritt Island, Florida · Not yet recruiting
Visionary Investigator Network
Miami, Florida · Recruiting
Visionary Investigator Network
Miami, Florida · Recruiting
Clinical Site Partners, LLC dba Flourish Research
Winter Park, Florida · Recruiting
Center for Advanced Research & Education LLC dba Flourish Research Gainesville
Gainesville, Georgia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.